Immunicum AB (publ) announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the company's therapeutic cancer vaccines. Immunicum's vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a unique refinement process are developed into highly immunogenic cells. The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.425 SEK | -0.30% | +1.63% | -19.46% |
06-27 | Transcript : Mendus AB - Special Call | |
05-17 | Transcript : Mendus AB, Q1 2024 Earnings Call, May 17, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.46% | 40.21M | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- IMMU Stock
- News Mendus AB
- Immunicum AB Receives Patent for the Production of Therapeutic Cancer Vaccines